UBS Starts AbCellera Biologics Coverage With Buy Rating
UBS began covering AbCellera Biologics with a Buy rating and set a target price of $18.00 per share, according to a Benzinga ratings update.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires, citing Benzinga’s ratings actions, reported that UBS initiated coverage of AbCellera Biologics with a Buy rating.
Benzinga said UBS announced an $18.00-per-share price target for AbCellera Biologics. The information was published on October 12, 2026, at 13:32 GMT.
why it matters
The report adds UBS’s assessment to the analyst coverage of AbCellera Biologics and identifies the price level the bank assigned to the shares.
instruments
sources
- AbCellera Biologics Initiated at Buy by UBS — Dow Jones Newswires, 12 October 2026 at 13:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗